# CXApp Inc.: financial statements, quarterly

CXAI · Nasdaq · CIK 1820875 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cxai.md) · [Financials](/companies/cxai/financials.md) · [Filings](/companies/cxai/filings.md) · [Insiders](/companies/cxai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cxai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [1,818](/filings/0001829126-25-003841.md) | [1,766](/filings/0001829126-25-006141.md) | [1,897](/filings/0001829126-25-009077.md) | [1,661 d](/filings/0001829126-26-002840.md) | [1,224](/filings/0001829126-26-005103.md) | [1,223](/filings/0001829126-26-008907.md) | [1,114](/filings/0001829126-25-009077.md) | [1,022 d](/filings/0001829126-26-002840.md) | [950](/filings/0001829126-26-005103.md) | [1,694](/filings/0001829126-26-008907.md) |
| Cost of revenue | $k | not reported | not reported | [327](/filings/0001829126-25-003841.md) | [353](/filings/0001829126-25-006141.md) | [372](/filings/0001829126-25-009077.md) | [233 d](/filings/0001829126-26-002840.md) | [150](/filings/0001829126-26-005103.md) | [171](/filings/0001829126-26-008907.md) | [123](/filings/0001829126-25-009077.md) | [134 d](/filings/0001829126-26-002840.md) | [160](/filings/0001829126-26-005103.md) | [623](/filings/0001829126-26-008907.md) |
| Gross profit | $k | not reported | not reported | [1,491](/filings/0001829126-26-002840.md) | [1,413](/filings/0001829126-26-002840.md) | [1,525](/filings/0001829126-26-002840.md) | [1,428](/filings/0001829126-26-002840.md) | [1,074](/filings/0001829126-26-005103.md) | [1,052](/filings/0001829126-26-008907.md) | [991](/filings/0001829126-26-002840.md) | [888](/filings/0001829126-26-002840.md) | [790](/filings/0001829126-26-005103.md) | [1,071](/filings/0001829126-26-008907.md) |
| Research and development | $k | not reported | not reported | [1,599](/filings/0001829126-25-003841.md) | [1,731](/filings/0001829126-25-006141.md) | [1,552](/filings/0001829126-25-009077.md) | [1,498 d](/filings/0001829126-26-002840.md) | [1,476](/filings/0001829126-26-005103.md) | [2,193](/filings/0001829126-26-008907.md) | [1,475](/filings/0001829126-25-009077.md) | [1,492 d](/filings/0001829126-26-002840.md) | [1,502](/filings/0001829126-26-005103.md) | [1,688](/filings/0001829126-26-008907.md) |
| Operating income | $k | [(1,097)](/filings/0001410578-22-003021.md) | [(1,229) d](/filings/0001410578-23-000755.md) | [(3,587)](/filings/0001829126-25-003841.md) | [(3,650)](/filings/0001829126-25-006141.md) | [(3,685)](/filings/0001829126-25-009077.md) | [(2,819) d](/filings/0001829126-26-002840.md) | [(3,745)](/filings/0001829126-26-005103.md) | [(4,111)](/filings/0001829126-26-008907.md) | [(3,825)](/filings/0001829126-25-009077.md) | [(5,896) d](/filings/0001829126-26-002840.md) | [(4,124)](/filings/0001829126-26-005103.md) | [(4,119)](/filings/0001829126-26-008907.md) |
| Interest expense | $k | not reported | not reported | [320](/filings/0001829126-25-003841.md) | [322](/filings/0001829126-25-006141.md) | [317](/filings/0001829126-25-009077.md) | [111 d](/filings/0001829126-26-002840.md) | [2.0](/filings/0001829126-25-003841.md) | [0.0](/filings/0001829126-25-006141.md) | [0.0](/filings/0001829126-25-009077.md) | [0.0 d](/filings/0001829126-26-002840.md) | not reported | not reported |
| Income tax | $k | [3.9](/filings/0001410578-22-003021.md) | [22.4 d](/filings/0001410578-23-000755.md) | [(207)](/filings/0001829126-25-003841.md) | [(159)](/filings/0001829126-25-006141.md) | [(147)](/filings/0001829126-25-009077.md) | [(122) d](/filings/0001829126-26-002840.md) | not reported | [1.0](/filings/0001829126-25-006141.md) | [0.0 d](/filings/0001829126-25-009077.md) | [(47.0) d](/filings/0001829126-26-002840.md) | [2.0](/filings/0001829126-26-005103.md) | not reported |
| Net income | $k | [872](/filings/0001410578-22-003021.md) | [(1,177) d](/filings/0001410578-23-000755.md) | [(5,170)](/filings/0001829126-25-003841.md) | [(5,256)](/filings/0001829126-25-006141.md) | [(5,434)](/filings/0001829126-25-009077.md) | [(3,978)](/filings/0001829126-26-002840.md) | [(1,616)](/filings/0001829126-26-005103.md) | [(3,139)](/filings/0001829126-26-008907.md) | [(3,157)](/filings/0001829126-25-009077.md) | [(5,561)](/filings/0001829126-26-002840.md) | [(4,003)](/filings/0001829126-26-005103.md) | [(8,620)](/filings/0001829126-26-008907.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

## Balance sheet

| Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.2](/filings/0001410578-23-000755.md) | not reported | not reported | not reported | not reported | [4.9](/filings/0001829126-26-002840.md) | [3.9](/filings/0001829126-25-003841.md) | [4.9](/filings/0001829126-25-006141.md) | [5.1](/filings/0001829126-25-009077.md) | [11.1](/filings/0001829126-26-008907.md) | [12.3](/filings/0001829126-26-005103.md) | [11.7](/filings/0001829126-26-008907.md) |
| Current assets | $m | [8.8](/filings/0001829126-24-003713.md) | [9.0](/filings/0001829126-24-003713.md) | not reported | not reported | not reported | [7.1](/filings/0001829126-26-002840.md) | [5.3](/filings/0001829126-25-003841.md) | [6.2](/filings/0001829126-25-006141.md) | [6.0](/filings/0001829126-25-009077.md) | [12.8](/filings/0001829126-26-008907.md) | [14.2](/filings/0001829126-26-005103.md) | [13.5](/filings/0001829126-26-008907.md) |
| Total assets | $m | [33.4](/filings/0001829126-24-003713.md) | [36.6](/filings/0001829126-24-003713.md) | not reported | not reported | not reported | [31.8](/filings/0001829126-26-002840.md) | [29.3](/filings/0001829126-25-003841.md) | [29.6](/filings/0001829126-25-006141.md) | [28.5](/filings/0001829126-25-009077.md) | [32.4](/filings/0001829126-26-008907.md) | [33.0](/filings/0001829126-26-005103.md) | [36.5](/filings/0001829126-26-008907.md) |
| Current liabilities | $m | [8.6](/filings/0001829126-24-003713.md) | [10.3](/filings/0001829126-24-003713.md) | not reported | not reported | not reported | [11.6](/filings/0001829126-26-002840.md) | [9.3](/filings/0001829126-25-003841.md) | [7.7](/filings/0001829126-25-006141.md) | [6.7](/filings/0001829126-25-009077.md) | [5.8](/filings/0001829126-26-008907.md) | [6.2](/filings/0001829126-26-005103.md) | [8.2](/filings/0001829126-26-008907.md) |
| Total liabilities | $m | [9.8](/filings/0001829126-24-003713.md) | [11.2](/filings/0001829126-24-003713.md) | not reported | not reported | not reported | [16.2](/filings/0001829126-26-002840.md) | [13.7](/filings/0001829126-25-003841.md) | [15.3](/filings/0001829126-25-006141.md) | [13.3](/filings/0001829126-25-009077.md) | [18.4](/filings/0001829126-26-008907.md) | [17.0](/filings/0001829126-26-005103.md) | [18.5](/filings/0001829126-26-008907.md) |
| Shareholders' equity | $m | [23.6](/filings/0001829126-24-003713.md) | [25.4](/filings/0001829126-26-002840.md) | [20.9](/filings/0001829126-25-009077.md) | [16.3](/filings/0001829126-25-009077.md) | [13.6](/filings/0001829126-25-009077.md) | [15.6](/filings/0001829126-26-008907.md) | [15.6](/filings/0001829126-26-008907.md) | [14.3](/filings/0001829126-26-008907.md) | [15.2](/filings/0001829126-25-009077.md) | [14.0](/filings/0001829126-26-008907.md) | [15.9](/filings/0001829126-26-008907.md) | [18.1](/filings/0001829126-26-008907.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(318) d](/filings/0001410578-22-003021.md) | [(146) d](/filings/0001410578-23-000755.md) | [(650)](/filings/0001829126-25-003841.md) | [(1,910) d](/filings/0001829126-25-006141.md) | [(2,069) d](/filings/0001829126-25-009077.md) | [(2,696) d](/filings/0001829126-26-002840.md) | [(979)](/filings/0001829126-26-005103.md) | [(3,012) d](/filings/0001829126-26-008907.md) | [(2,759) d](/filings/0001829126-25-009077.md) | [(3,631) d](/filings/0001829126-26-002840.md) | [(2,210)](/filings/0001829126-26-005103.md) | [(2,245) d](/filings/0001829126-26-008907.md) |
| Capital expenditure | $k | not reported | not reported | [18.0](/filings/0001829126-25-003841.md) | [8.0 d](/filings/0001829126-25-006141.md) | [4.0 d](/filings/0001829126-25-009077.md) | [0.0 d](/filings/0001829126-26-002840.md) | [5.0](/filings/0001829126-26-005103.md) | [11.0 d](/filings/0001829126-26-008907.md) | [5.0 d](/filings/0001829126-25-009077.md) | [2.0 d](/filings/0001829126-26-002840.md) | not reported | not reported |
| Share repurchases | $k | [0.0 d](/filings/0001410578-22-003021.md) | [5,574 d](/filings/0001410578-23-000755.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 116,870,315 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001829126-26-008907.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.